%0 Journal Article
%A Coltin, Hallie
%A Sundaresan, Lakshmikirupa
%A Smith, Kyle S
%A Skowron, Patryk
%A Massimi, Luca
%A Eberhart, Charles G
%A Schreck, Karisa C
%A Gupta, Nalin
%A Weiss, William A
%A Tirapelli, Daniela
%A Carlotti, Carlos
%A Li, Kay K W
%A Ryzhova, Marina
%A Golanov, Andrey
%A Zheludkova, Olga
%A Absalyamova, Oksana
%A Okonechnikov, Konstantin
%A Stichel, Damian
%A von Deimling, Andreas
%A Giannini, Caterina
%A Raskin, Scott
%A Van Meir, Erwin G
%A Chan, Jennifer A
%A Fults, Daniel
%A Chambless, Lola B
%A Kim, Seung-Ki
%A Vasiljevic, Alexandre
%A Faure-Conter, Cecile
%A Vibhakar, Rajeev
%A Jung, Shin
%A Leary, Sarah
%A Mora, Jaume
%A McLendon, Roger E
%A Pollack, Ian F
%A Hauser, Peter
%A Grajkowska, Wieslawa A
%A Rubin, Joshua B
%A van Veelen, Marie-Lise C
%A French, Pim J
%A Kros, Johan M
%A Liau, Linda M
%A Pfister, Stefan M
%A Kool, Marcel
%A Kijima, Noriyuki
%A Taylor, Michael D
%A Packer, Roger J
%A Northcott, Paul A
%A Korshunov, Andrey
%A Ramaswamy, Vijay
%T Subgroup and subtype-specific outcomes in adult medulloblastoma.
%J Acta neuropathologica
%V 142
%N 5
%@ 1432-0533
%C Heidelberg
%I Springer
%M DKFZ-2021-01895
%P 859-871
%D 2021
%Z #LA:B300# / 2021 Nov;142(5):859-871
%X Medulloblastoma, a common pediatric malignant central nervous system tumour, represent a small proportion of brain tumours in adults. Previously it has been shown that in adults, Sonic Hedgehog (SHH)-activated tumours predominate, with Wingless-type (WNT) and Group 4 being less common, but molecular risk stratification remains a challenge. We performed an integrated analysis consisting of genome-wide methylation profiling, copy number profiling, somatic nucleotide variants and correlation of clinical variables across a cohort of 191 adult medulloblastoma cases identified through the Medulloblastoma Advanced Genomics International Consortium. We identified 30 WNT, 112 SHH, 6 Group 3, and 41 Group 4 tumours. Patients with SHH tumours were significantly older at diagnosis compared to other subgroups (p < 0.0001). Five-year progression-free survival (PFS) for WNT, SHH, Group 3, and Group 4 tumours was 64.4 (48.0-86.5), 61.9
%K Adult (Other)
%K DNA methylation profiling (Other)
%K Medulloblastoma (Other)
%K Molecular groups (Other)
%K Risk stratification (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34409497
%R 10.1007/s00401-021-02358-4
%U https://inrepo02.dkfz.de/record/170386